Cristina Maccalli, PhD

Principal Investigator – Assistant Level Laboratory of Immune Biological Therapy

Email: cmaccalli (@) sidra.org

SELECTED PUBLICATIONS(equal contribution, *corresponding):

  1. Tomei S, Ibnaof O, Ravindran S, Ferrone S, Maccalli C*. Cancer Stem Cells Are Possible Key Players in Regulating Anti-Tumor Immune Responses: The Role of Immunomodulating Molecules and MicroRNAs. Cancers (Basel). 13:1674. doi: 10.3390/cancers13071674. 
  2. Tomei S, Volontè A, Ravindran S, Mazzoleni S, Wang E, Galli R, Maccalli C. MicroRNA Expression Profile Distinguishes Glioblastoma Stem Cells from Differentiated Tumor Cells. J Pers Med. 2021 11:264. doi: 10.3390/jpm11040264.
  3.  Guerrouahen B., Elnaggar M., Al-Mohannadi A., Kizhakayil D., Bonini C., Reuben B., Brentjer R., Buchholz C., Casorati G., Ferrone S., Locke F., Martin F., Schambach A., Turtle C., Veys P., van der Vliet A.J-J.-EICCI Faculty, Maccalli C.* “Proceedings from the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): from Discovery to Off-the-Shelf Development. Front. Immunol., 14 January 2021 https://doi.org/10.3389/fimmu.2020.589381.
  4.  Maccalli C. Translational cancer biology. 2020. J Transl Med. Sep 23;18(1):364. doi: 10.1186/s12967-020-02537-z.
  5. Pilla L., Alberti A., Di Mauro P., Gemelli M., Cogliati V., Cazzaniga ME., BidoliP. and Maccalli C. “Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future ProspectsCancers 2020, 12(11), 3456; https://doi.org/10.3390/cancers12113456 - 20 Nov 2020.
  6.  Lieskovan S-H., Bhaumik S., Dhodapkar K., Grivel J-C., Gupta S., Hanks BA., Janetzki S., O Kleen T., Koguchi Y., Lund AW., Maccalli C., Mahnke YD., Novosiadly RD., Selvan S.R., Sims T., Zhao Y. and Maecker HT. SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery “ J. Immunoth. Cancer, December 2020 (Position marker and guideline) http://dx.doi.org/10.1136/jitc-2020-000705 
  7. Gotti M., Defrancesco I., D'angelo M., Basso S., Crotto L., Marinelli A., Maccalli C., Iaconianni V. “Cancer Immunotherapy using Chimeric Antigen Receptor (CAR) expressing T cells: present and future needs of clinical cancer centers”.  Frontiers in Immunology. https://doi.org/10.3389/fimmu.2020.565236 
  8. Rovida A., Maccalli C., Scarfò L., Dellabona P., Stamatopoulos K. and Ghia P. “Exploiting B Cell Receptor Stereotypy to design Tailored Immunotherapy in Chronic Lymphocytic Leukemia” DOI: 10.1158/1078-0432.CCR-20-1632
  9. Guerrouahen BS, Maccalli C, Cugno C, Rutella S, Akporiaye ET. Reverting Immune Suppression to Enhance Cancer Immunotherapy. Front Oncol. 2020 Jan 21;9:1554. doi: 10.3389/fonc.2019.01554. eCollection 2019.
  10. Ravindran S, Rasool S, Maccalli C*. The Cross Talk between Cancer Stem Cells/Cancer Initiating Cells and Tumor Microenvironment: The Missing Piece of the Puzzle for the Efficient Targeting of these Cells with Immunotherapy. Cancer Microenviron. 2019 Nov 22. doi: 10.1007/s12307-019-00233-1.
  11. Maccalli C*, Rasul K, Elawad M, Ferrone S. The role of cancer stem cells in the modulation of anti-tumor immune responses. Semin Cancer Biol. 2018 Sep 24. pii: S1044-579X(18)30044-0. doi: 10.1016/j.semcancer.2018.09.006.
  12.  Pilla L, Maccalli C*. Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges. Biomedicines. 2018 Jul 2;6(3). pii: E76. doi: 10.3390/biomedicines6030076.
  13. Pilla L, Ferrone S, Maccalli C*. Methods for improving the immunogenicity and efficacy of cancer vaccines. Expert Opin Biol Ther. 2018 Jul;18(7):765-784. doi: 10.1080/14712598.2018.1485649. Epub 2018 Jun 17.